3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
2400
Neoplasms
1819
Carcinoma, Non-Small-Cell Lung
1599
Prostatic Neoplasms
1298
Colorectal Neoplasms
1140
Lung Neoplasms
984
Neoplasm Metastasis
830
Multiple Myeloma
792
Leukemia, Myeloid, Acute
767
Ovarian Neoplasms
674
Pancreatic Neoplasms
662
Melanoma
660
Squamous Cell Carcinoma of Head and Neck
586
Carcinoma, Hepatocellular
567
Recurrence
562
Brain Neoplasms
527
Glioblastoma
513
Head and Neck Neoplasms
500
Stomach Neoplasms
497
Triple Negative Breast Neoplasms
465
Lymphoma
454
Uterine Cervical Neoplasms
450
Carcinoma, Renal Cell
425
Precursor Cell Lymphoblastic Leukemia-Lymphoma
410
Lymphoma, Non-Hodgkin
389
Endometrial Neoplasms
381
Sarcoma
368
Lymphoma, Follicular
356
Urinary Bladder Neoplasms
354
Hematologic Neoplasms
352
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Biochemically Recurrent Prostate Cancer
×
1 year
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts